These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26586793)

  • 21. Low expression of RecQ-like helicase 5 is associated with poor prognosis in patients with gastric cancer.
    Lin Y; Wang H; Wang X; Li M; Chen H; Peng J
    Oncol Lett; 2020 Jan; 19(1):985-991. PubMed ID: 31897211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allelic imbalance at the HER2/TOP2A locus in breast cancer.
    Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH
    Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.
    Fritz P; Cabrera CM; Dippon J; Gerteis A; Simon W; Aulitzky WE; van der Kuip H
    Breast Cancer Res; 2005; 7(3):R374-84. PubMed ID: 15987433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
    Kurozumi S; Joseph C; Sonbul S; Gorringe KL; Pigera M; Aleskandarany MA; Diez-Rodriguez M; Nolan CC; Fujii T; Shirabe K; Kuwano H; Storr S; Martin SG; Ellis IO; Green AR; Rakha EA
    Breast Cancer Res Treat; 2018 Aug; 170(3):525-533. PubMed ID: 29633055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
    Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preserved Axin expression is associated with an aggressive phenotype in invasive breast carcinomas.
    Irini T; Paraskevi A; Ioanna G; Christos P; Lydia N
    APMIS; 2013 Sep; 121(9):797-805. PubMed ID: 23278310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct prognosis of mRNA expression of the five RecQ DNA-helicase family members -
    Zhu X; Chen H; Yang Y; Xu C; Zhou J; Zhou J; Chen Y
    Cancer Manag Res; 2018; 10():6649-6668. PubMed ID: 30584360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
    Alshareeda AT; Negm OH; Albarakati N; Green AR; Nolan C; Sultana R; Madhusudan S; Benhasouna A; Tighe P; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2013 Jun; 139(2):301-10. PubMed ID: 23624778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
    Joseph C; Al-Izzi S; Alsaleem M; Kurozumi S; Toss MS; Arshad M; Goh FQ; Alshankyty IM; Aleskandarany MA; Ali S; Ellis IO; Mongan NP; Green AR; Rakha EA
    Br J Cancer; 2019 Oct; 121(9):776-785. PubMed ID: 31558802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA repair gene expression and risk of locoregional relapse in breast cancer patients.
    Le Scodan R; Cizeron-Clairac G; Fourme E; Meseure D; Vacher S; Spyratos F; de la Lande B; Cvitkovic F; Lidereau R; Bieche I
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):328-36. PubMed ID: 20092964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer.
    Wu J; Zong Y; Fei X; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
    PLoS One; 2014; 9(8):e98673. PubMed ID: 25153161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy.
    Patterson K; Arya L; Bottomley S; Morgan S; Cox A; Catto J; Bryant HE
    Oncotarget; 2016 Nov; 7(46):76140-76150. PubMed ID: 27764811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The deubiquitinase USP28 stabilizes the expression of RecQ family helicases and maintains the viability of triple negative breast cancer cells.
    Wang J; Dong Y; Ma H; Wu L; Zhen X; Tang L; Jin J; Han S; Zhang P; Peng J
    J Biol Chem; 2022 Jan; 298(1):101443. PubMed ID: 34822842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
    Santarpia L; Iwamoto T; Di Leo A; Hayashi N; Bottai G; Stampfer M; André F; Turner NC; Symmans WF; Hortobágyi GN; Pusztai L; Bianchini G
    Oncologist; 2013; 18(10):1063-73. PubMed ID: 24072219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.
    Mylona E; Magkou C; Giannopoulou I; Agrogiannis G; Markaki S; Keramopoulos A; Nakopoulou L
    Breast Cancer Res; 2006; 8(5):R57. PubMed ID: 17032447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.
    Zhang X; Zhang Y; Yang Y; Niu M; Sun S; Ji H; Ma Y; Yao G; Jiang Y; Shan M; Zhang G; Pang D
    Cancer Epidemiol; 2012 Jun; 36(3):288-93. PubMed ID: 21889920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.